Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M

Enliven Therapeutics, Inc.

2025-Q1 EPS reported -$0.57

Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.
Cash, equivalents and marketable securities $289.6M; runway into late 2027.
ELVN-001 Phase 1 ENABLE: 44% (16/36) cumulative MMR by 24 weeks, well-tolerated, 74 patients.
Strategic alternatives for ELVN-002 program; not pursued beyond 2025 to extend cash runway.
Updated ELVN-001 data to be presented at EHA Congress in June; webcast June 13.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.